Shanghai Haohai Biological Tech Co (688366) fair value: what the stock is really worth
As of Sep 24, 2026: fair value of Shanghai Haohai Biological Tech Co ¥33.44, price ¥29.91, upside +11.8%, quality 66 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Shanghai Haohai Biological Tech Co for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.
How to read this chart
60‑month range ¥28.61 – ¥190.85 · fair‑value band ¥25.08 – ¥41.39 · the ¥29.91 price screens below the ¥33.44 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 24, 2026.
Follow Shanghai Haohai Biological Tech Co in your weekly email
Every Wednesday you see whether Shanghai Haohai Biological Tech Co is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Shanghai Haohai Biological Technology Co., Ltd. engages in the research, development, manufacture, and sale of biomedical materials in Mainland China, Europe, the United States, and internationally.
Show more
Shanghai Haohai Biological Technology Co., Ltd. engages in the research, development, manufacture, and sale of biomedical materials in Mainland China, Europe, the United States, and internationally. The company offers ophthalmic implants, assistive devices, and medical devices; medical optical instruments, including intraocular lenses, endoscopic equipment, ophthalmic surgical instruments, and other ophthalmic medical products; hyaluronic acid and chitosan; and electronic instruments, such as semiconductors, optoelectronics, lasers, radio frequency, and ultrasonic instruments. It also engages in the research and development of biological engineering and pharmaceutical products and related technology transfer activities, consulting, and other services; research, development, production, and sales of radio frequency instruments; cell technology and biochemical product technology research and development; computer, communication, and other electronic equipment manufacturing; instrument manufacturing; manufacture and sale of biological reagents, biological agents, and biological materials; medical-grade sodium hyaluronate bio-based skincare products; intraocular lens and related products; intraocular lens injectors and materials, equipment, chemical products, and accessories for contact lenses and artificial lenses; sale of ophthalmology products; and provision of other machines and accessories. In addition, the company is involved in property management; business management consulting; non-residential real estate leasing; provision of technical services, technology promotion, development and transfer, technical consulting and exchange; wholesale of cosmetics; import and export of goods; import and export of technology; and information technology consulting services. The company was formerly known as Haohai Limited and changed its name to Shanghai Haohai Biological Technology Co., Ltd. in 2010. The company was founded in 2007 and is headquartered in Shanghai, China.
Stock analysis
Shanghai Haohai Biological Tech Co (688366) currently trades at ¥29.91, while our model-based Fair Value estimate is ¥33.44, implying the stock looks roughly 10.6% undervalued today.
Show more
Valuation
Bull case: the DCF Models group reads highest at a median of ¥36.86 per share, and 9 of the 26 models we run sit above the ¥29.91 price.
Bear case: the Dividend Discount group reads lowest at ¥12.59, and 17 of the 26 models stay below the price. Evidence for this calculation is high.
Scenario range: ¥25.08 (bear) to ¥41.39 (bull), the price of ¥29.91 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 66/100 (solid quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Shanghai Haohai Biological Tech Co reported revenue of 2.5B CNY in FY2025 versus 1.8B CNY in FY2021, a compound +9.0%/yr. Reported net income was 251M CNY in FY2025, compounding −8.1%/yr from FY2021.
Key figures
Market cap 7.0B CNY (≈ $1.0B) · P/E ratio 30.6 · P/S ratio 3.11 · EPS (TTM) ¥1.08 · Dividend yield 3.3% · Net margin 10.1% · Return on equity 3.4% · Return on assets (EBIT) 3.6%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 48 out of 100 (low confidence).
What moves the price
The share trades about 43% below its 52-week high and 5% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −5% fair-value upside, at 12%, 688366 screens cheaper than that median.
Fair Value models
Bear ¥25.08Fair Value ¥33.44Bull ¥41.39
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 9 months old). Earnings retained since then (¥0.0587 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.83/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
−7.7%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+5.5%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+13.3%
Start year 2020 (pandemic). Over 10 years: +14.1% a year
Revenue growth 13 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+17.5%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
+4.4%
Earnings growth per share plus dividend.
Earnings per share, growth per year+1.1%
Dividend (yield on the price)3.3%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.1% vs 1%, steady
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.6% → 9%
Start year 2020 (pandemic)
Growth Forecast
Little optimism in the price
The price assumes less growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+6.8%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (China: IMF forecast 1.7% a year to 2030, 1.4% from 2016 to 2025) that is about +5.0% a year for the price.
Compare Shanghai Haohai Biological Tech Co with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 650 stocks
Beats the industry median on 12/14 measures
Overall it ranks above its industry peers.
Valuation
Quality Score66 · Top 25%
Fair Value upside+10% · Top 25%
Profitability
Return on equity (TTM)3% · Above median
Return on assets2% · Top 25%
Net margin (TTM)10% · Above median
Operating margin (TTM)13% · Above median
Growth and dividend
Revenue growth−8% · Below median
Dividend yield (TTM)3.3% · Top 25%
Balance sheet
Debt / equity0.01× · Below median
Valuation Multiplesvs Biotechnology median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Shanghai Haohai Biological Tech Co Fair Value". https://www.fairvalue-calculator.com/stock/688366
Frequently asked questions
Is Shanghai Haohai Biological Tech Co (688366) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of ¥33.44 versus a price of ¥29.91, about +12% upside (undervalued).
What is the fair value of 688366?
Our model-based fair value for Shanghai Haohai Biological Tech Co is ¥33.44 (as of Sep 24, 2026), built from audited fundamentals. The current price: ¥29.91.
What is the quality score of 688366?
Shanghai Haohai Biological Tech Co has a Quality Score of 66/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Shanghai Haohai Biological Tech Co (688366)?
Our model-based price target is the fair value of ¥33.44 (as of Sep 24, 2026) from 26 valuation models. Cautious scenario ¥25.08, optimistic scenario ¥41.39. It is a calculation from audited fundamentals, not an analyst target.
What is the Shanghai Haohai Biological Tech Co stock forecast for 2026?
Our models put fair value at ¥33.44, about +12% upside versus a price of ¥29.91 (undervalued). Cautious scenario ¥25.08, optimistic scenario ¥41.39. The calculation is refreshed regularly with new filings.
What is the revenue of Shanghai Haohai Biological Tech Co (688366)?
Shanghai Haohai Biological Tech Co reported trailing-twelve-month revenue of about 2.4B CNY (latest available figure, as of Sep 24, 2026).
Does Shanghai Haohai Biological Tech Co pay a dividend?
Shanghai Haohai Biological Tech Co currently shows a dividend yield of about 3.34% relative to its recent price (as of Sep 24, 2026).
What growth is priced into Shanghai Haohai Biological Tech Co (688366)?
For today's price to be fair in a discounted-cash-flow model, Shanghai Haohai Biological Tech Co would have to grow free cash flow by +6.8 % per year for five years (discount rate 10.4 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +13.3 % per year. As of Sep 24, 2026.
What discount rate (WACC) does the fair value of 688366 use?
Our models discount Shanghai Haohai Biological Tech Co at 10.4 %: a base by market capitalisation (small), damped by beta 0.47, country premium for China. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Shanghai Haohai Biological Tech Co that is +6.8 % per year a year over ten years, using the same discount rate (10.4 %) and the same formula as our fair value.
How much growth has Shanghai Haohai Biological Tech Co (688366) delivered so far?
Over the past 5 years revenue at Shanghai Haohai Biological Tech Co grew +13.3 % a year. The price currently implies +6.8 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Shanghai Haohai Biological Tech Co (688366) growing?
The median revenue growth in the sector is +4.2 % a year. That is the yardstick for the growth priced into Shanghai Haohai Biological Tech Co (+6.8 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Shanghai Haohai Biological Tech Co (688366)?
The free-cash-flow yield on the price is 4.37 %: that much free cash flow Shanghai Haohai Biological Tech Co produces per unit of market value. When it exceeds the discount rate of our models (10.4 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Shanghai Haohai Biological Tech Co (688366)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Shanghai Haohai Biological Tech Co it is ¥33.44 per share (as of Sep 24, 2026), against a price of ¥29.91. It is the blended result of 26 valuation models (cash flow, earnings, asset, dividend).
Is Shanghai Haohai Biological Tech Co stock overvalued or undervalued in 2026?
As of Sep 24, 2026, 688366 trades below its calculated fair value: price ¥29.91, fair value ¥33.44, a gap of about +12% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 688366?
No. The price is what the market pays today (¥29.91); the fair value is what the company's own numbers justify (¥33.44). For Shanghai Haohai Biological Tech Co the two are ¥3.53 per share apart. That gap is exactly why we show both numbers side by side.
How much is Shanghai Haohai Biological Tech Co worth?
The market values Shanghai Haohai Biological Tech Co at about 7.0B CNY (market capitalisation, as of Sep 24, 2026). Per share that is ¥29.91; our models calculate a fair value of ¥33.44 per share.
What do the bullish and bearish scenarios say about 688366?
Our models span a range for Shanghai Haohai Biological Tech Co: cautious scenario ¥25.08, base ¥33.44, optimistic ¥41.39 per share (as of Sep 24, 2026, price ¥29.91). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 688366?
Shanghai Haohai Biological Tech Co trades at a price-to-earnings ratio of 30.6 (as of Sep 24, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of ¥33.44 is built from several models across several years. Other multiples: P/B 1.3, P/S 2.9, EV/EBITDA 11.8.
How solid is the balance sheet of Shanghai Haohai Biological Tech Co (688366)?
Balance-sheet figures for Shanghai Haohai Biological Tech Co (as of Sep 24, 2026): return on equity 3.4%, debt of 0.01 per unit of equity. They feed the Quality Score of 66/100, which measures business quality independently of the share price.
How far is 688366 from its 52-week high?
Shanghai Haohai Biological Tech Co trades at ¥29.91, about 43% below its 52-week high of ¥52.20 and 5% above the low of ¥28.61 (as of Sep 24, 2026). Distance from the high says nothing about value: that is what the fair value of ¥33.44 is for.
Which stocks are comparable to Shanghai Haohai Biological Tech Co?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, Samsung Biologics Co, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Shanghai Haohai Biological Tech Co stock attractive at the current price?
The data as of Sep 24, 2026: price ¥29.91, calculated fair value ¥33.44 (+12%), Quality Score 66/100, from 26 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 688366 calculated?
We run Shanghai Haohai Biological Tech Co through 26 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of ¥33.44, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.2 % above its aggregate fair value. Shanghai Haohai Biological Tech Co currently trades 12 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Shanghai Haohai Biological Tech Co (688366)?
The closing price on Sep 24, 2026 was ¥29.91. Our model-based fair value is ¥33.44, about +12% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Shanghai Haohai Biological Tech Co right now?
The price sits in the lower half of our model range, the side with the larger margin of safety. The data supports the verdict: every model runs on fully documented inputs.
Where does the earnings growth of Shanghai Haohai Biological Tech Co (688366) come from?
Earnings per share at Shanghai Haohai Biological Tech Co grew +6.1 % a year from 2014 to 2025. Broken into its drivers: revenue per share +18.4 %, EBIT margin −11.0 %, tax rate +0.2 %, residual (interest, one-offs) +0.5 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.
Key figures of Shanghai Haohai Biological Tech Co
How large is the market capitalisation of Shanghai Haohai Biological Tech Co (688366)?
The market capitalisation of Shanghai Haohai Biological Tech Co is 7.0B CNY (≈ $1.0B). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Shanghai Haohai Biological Tech Co (688366)?
The price-to-sales ratio of Shanghai Haohai Biological Tech Co is 3.11 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Shanghai Haohai Biological Tech Co (688366)?
Earnings per share at Shanghai Haohai Biological Tech Co are ¥1.08 (price ÷ EPS = P/E 30.6). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Shanghai Haohai Biological Tech Co (688366)?
The dividend yield of Shanghai Haohai Biological Tech Co is 3.3% (payout 92.6%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Shanghai Haohai Biological Tech Co (688366)?
The net margin of Shanghai Haohai Biological Tech Co is 10.1% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Shanghai Haohai Biological Tech Co (688366)?
The return on equity (ROE) of Shanghai Haohai Biological Tech Co is 3.4% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Shanghai Haohai Biological Tech Co (688366)?
On an EBIT basis the return on assets of Shanghai Haohai Biological Tech Co is 3.6% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Shanghai Haohai Biological Tech Co (688366)?
The operating margin of Shanghai Haohai Biological Tech Co is 13.1% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Shanghai Haohai Biological Tech Co (688366)?
Revenue at Shanghai Haohai Biological Tech Co is growing −7.6% versus a year earlier (3y avg +5.5%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Shanghai Haohai Biological Tech Co (688366)?
Earnings per share at Shanghai Haohai Biological Tech Co are growing −17.9% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net cash does Shanghai Haohai Biological Tech Co (688366) hold?
Shanghai Haohai Biological Tech Co holds more cash than debt, 2.0B CNY net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch Shanghai Haohai Biological Tech Co in the live analysis
One click puts Shanghai Haohai Biological Tech Co on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
